See why Sapient is preferred among multi-omics companies for large-scale metabolomics and proteomics studies exploring the dynamic factors modulating disease and drug response.
While the vast majority of biomarker discovery to date has focused on genomics, >80% of disease risk stems from non-genetic factors and exposures over time. This molecular landscape has remained largely unexplored, until now.
Sapient’s innovative technologies finally enable rapid, large-scale multi-omics biomarker discovery beyond the genome.
We comprehensively profile metabolite, lipid, and protein biomarkers, which read out dynamic factors influencing health and disease – measuring thousands of biomarkers per sample, across thousands of samples at a time.
Capturing >15K small molecule biomarkers per biosample, including metabolites and lipids, with capacity to handle >5,000 samples per day.
Optimized approaches for interrogation of the plasma and tissue proteome, with our /Core/ Discovery method measuring 4,000+ proteins and PTMs in plasma.
Targeted, high-specificity measure of key proteins, metabolites, and lipids of interest, captured in a variety of liquid and tissue matrices.
Explore our integrative services for rapid multi-omics data generation & analysis and how they deliver unique value to accelerate your studies.
"*" indicates required fields
Looking for the best in multi-omics companies? Connect with our scientists to learn more about the differentiators of our services and the biological insights we deliver.
We’ll show you how they can be made actionable to advance your drug development programs, including through case studies that show our work with other top pharma and biotech innovators.
